IDOL, as an E3-ubiquitin ligase promoting the ubiquitination and degradation of hepatic LDLR, appears to be a promising therapeutic target for treating dyslipidemia and ASCVD.20 This evidence concerns the gene LDLR and metabolic syndrome.